Uwe Pelzer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2018528/publications.pdf

Version: 2024-02-01

86 papers	4,204 citations	201674 27 h-index	114465 63 g-index
94 all docs	94 docs citations	94 times ranked	5674 citing authors

#	Article	IF	Citations
1	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet, The, 2016, 387, 545-557.	13.7	878
2	Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial. Journal of Clinical Oncology, 2014, 32, 2423-2429.	1.6	397
3	Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group. European Journal of Cancer, 2011, 47, 1676-1681.	2.8	318
4	Efficacy of Prophylactic Lowâ€“Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. Journal of Clinical Oncology, 2015, 33, 2028-2034.	1.6	217
5	CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. Journal of Clinical Oncology, 2017, 35, 3330-3337.	1.6	215
6	Detection of recurrent pancreatic cancer: Comparison of FDG-PET with CT/MRI. Pancreatology, 2005, 5, 266-272.	1.1	152
7	Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia, 2018, 32, 1908-1919.	7.2	137
8	APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, 4000-4000.	1.6	125
9	Î±-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. British Journal of Cancer, 2014, 111, 1917-1923.	6.4	119
10	Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 128-138.	8.1	89
11	Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. European Journal of Cancer, 2017, 83, 290-301.	2.8	74
12	Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous	2.6	70
13	SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Annals of Oncology, 2014, 25, 1025-1032.	1.2	66
14	Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study. BMC Cancer, 2010, 10, 86.	2.6	63
15	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 1940-1951.	3.8	60
16	The Impact of Simultaneous Liver Resection for Occult Liver Metastases of Pancreatic Adenocarcinoma. Gastroenterology Research and Practice, 2012, 2012, 1-8.	1.5	57
17	Prognostic Factors for Long-Term Survival in Patients with Ampullary Carcinoma: The Results of a 15-Year Observation Period after Pancreaticoduodenectomy. HPB Surgery, 2014, 2014, 1-8.	2.2	51
18	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncology, The, 2018, 19, e151-e160.	10.7	51

#	Article	IF	Citations
19	A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. Annals of Oncology, 2000, 11, 1267-1272.	1.2	48
20	Does long-term survival in patients with pancreatic cancer really exist?-Results from the CONKO-001 study. Journal of Surgical Oncology, 2013, 108, 398-402.	1.7	41
21	Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine â€“ Results from the CONKO-001 trial. European Journal of Cancer, 2015, 51, 1546-1554.	2.8	40
22	Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Annals of Oncology, 2020, 31, 79-87.	1.2	36
23	CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeksâ€”A prospective randomized phase III study.. Journal of Clinical Oncology, 2015, 33, 4007-4007.	1.6	35
24	Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/IIa Study. Cancers, 2020, 12, 3130.	3.7	34
25	A phase Ib/IIa study of combination therapy with gemcitabine and Atu027 in patients with locally advanced or metastatic pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, 385-385.	1.6	34
26	Cancer-related neuropathic pain in out-patient oncology clinics: a European survey. BMC Palliative Care, 2013, 12, 41.	1.8	32
27	Blood group determinates incidence for pancreatic cancer in Germany. Frontiers in Physiology, 2013, 4, 118.	2.8	29
28	Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. British Journal of Cancer, 2018, 118, 1485-1491.	6.4	29
29	PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. , 2021, 9, e002844.		29
30	Treatment of Intrahepatic Cholangiocarcinomaâ€”A Multidisciplinary Approach. Cancers, 2022, 14, 362.	3.7	29
31	The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. Surgical Oncology, 2018, 27, 688-694.	1.6	28
32	TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial. Clinical Cancer Research, 2020, 26, 3732-3739.	7.0	28
33	Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Nature Communications, 2022, 13, 156.	12.8	28
34	Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy. Frontiers in Oncology, 2013, 3, 155.	2.8	26
35	Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. British Journal of Cancer, 2017, 116, 1247-1253.	6.4	25
36	Phase I trial of gemcitabine (GemzarÂ®), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer. Anti-Cancer Drugs, 1999, 10, 699-704.	1.4	24

#	Article	IF	Citations
37	Second-Line Treatment in Pancreatic Cancer Patients. Pancreas, 2016, 45, 601-605.	1.1	22
38	Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. World Journal of Gastrointestinal Oncology, 2016, 8, 248.	2.0	22
39	Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study. Oncology Research and Treatment, 2009, 32, 99-102.	1.2	21
40	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. Lancet Haematology,the, 2020, 7, e746-e755.	4.6	21
41	P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. Pathology Research and Practice, 2016, 212, 726-734.	2.3	19
42	Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. Frontiers in Oncology, 2021, 11, 670396.	2.8	19
43	Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy. Pancreas, 2015, 44, 930-936.	1.1	18
44	Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. BMJ Open, 2016, 6, e010569.	1.9	18
45	Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review. World Journal of Gastrointestinal Oncology, 2016, 8, 258.	2.0	18
46	Prognostic and Predictive Molecular Markers in Cholangiocarcinoma. Cancers, 2022, 14, 1026.	3.7	17
47	Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients. PLoS ONE, 2017, 12, e0186341.	2.5	15
48	A tailored approach in lymph node-positive perihilar cholangiocarcinoma. Langenbeck's Archives of Surgery, 2021, 406, 1499-1509.	1.9	15
49	Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer â€“ the CONKO 004 pilot trial. BMC Cancer, 2014, 14, 204.	2.6	14
50	The Falciform Ligament for Mesenteric and Portal Vein Reconstruction in Local Advanced Pancreatic Tumor: A Surgical Guide and Single-Center Experience. HPB Surgery, 2018, 2018, 1-8.	2.2	13
51	Routine portal vein resection for pancreatic adenocarcinoma shows no benefit in overall survival. European Journal of Surgical Oncology, 2018, 44, 1094-1099.	1.0	12
52	Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies?. Journal of Clinical Medicine, 2022, 11, 2367.	2.4	12
53	Non-invasive assessment of cardiac hemodynamics in patients with advanced cancer and with chronic heart failure: a pilot feasibility study. Archives of Medical Science, 2013, 2, 261-267.	0.9	10
54	Ultrasound Time-Harmonic Elastography of the Pancreas. Investigative Radiology, 2020, 55, 270-276.	6.2	9

#	Article	IF	Citations
55	Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine-versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP).. Journal of Clinical Oncology, 2018, 36, 348-348.	1.6	9
56	Hent1 expression in patients with pancreatic cancer treated with gemcitabine after curative intended resection: Results from the CONKO-001 trial.. Journal of Clinical Oncology, 2014, 32, 4124-4124.	1.6	8
57	Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemiaâ€"A retrospective analysis. European Journal of Cancer, 2018, 100, 85-93.	2.8	7
58	First-Line Chemotherapy in Advanced Pancreatic Cancer. , 2008, 177, 57-60.		7
59	Role of F18-FDG PET for Monitoring of Radiochemotherapy â€“ Estimation of Detectable Number of Tumour Cells. Oncology Research and Treatment, 2004, 27, 287-290.	1.2	6
60	First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group. Cancer Chemotherapy and Pharmacology, 2011, 68, 1173-1178.	2.3	6
61	Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: a multicentre, cluster-randomised trial within the German Interdisciplinary Sarcoma Group (GISG). BMJ Open, 2020, 10, e035546.	1.9	6
62	First-line nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer from routine clinical practice. In Vivo, 2014, 28, 1135-40.	1.3	6
63	Reply to M.G. McNamara et al and T.H. Oo. Journal of Clinical Oncology, 2016, 34, 516-517.	1.6	5
64	Influence of the body mass index on postoperative outcome and long-term survival after pancreatic resections in patients with underlying malignancy. Hepatobiliary Surgery and Nutrition, 2019, 8, 201-210.	1.5	5
65	Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer â€“ A Matched-Pair Analysis. Anticancer Research, 2019, 39, 5781-5787.	1.1	5
66	Influence of Baseline CT Body Composition Parameters on Survival in Patients with Pancreatic Adenocarcinoma. Journal of Clinical Medicine, 2022, 11, 2356.	2.4	5
67	Split-bolus vs. multiphasic contrast bolus protocol in patients with pancreatic cancer or cholangiocarcinoma. European Journal of Radiology, 2019, 119, 108626.	2.6	4
68	Fechtner syndromeâ€"a myosin heavy chain 9 disorderâ€"and pregnancy. International Journal of Gynecology and Obstetrics, 2010, 109, 163-164.	2.3	3
69	Strengths, Weaknesses, Opportunities, and Threats of Centralized Pancreatic Surgery: a Single-Center Analysis of 3000 Consecutive Pancreatic Resections. Journal of Gastrointestinal Surgery, 2019, 23, 492-502.	1.7	3
70	Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma â€“ A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials. European Journal of Cancer, 2021, 150, 250-259.	2.8	3
71	Second-Line Chemotherapy in Advanced Pancreatic Cancer. , 2008, 177, 61-64.		3
72	Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer. Journal of Surgical Oncology, 2015, 112, 66-71.	1.7	2

#	Article	IF	Citations
73	Accomplishments in 2008 in the treatment of metastatic pancreatic cancer. Gastrointestinal Cancer Research: GCR, 2009, 3, S43-7.	0.7	2
74	The Role of Immunosuppression for Recurrent Cholangiocellular Carcinoma after Liver Transplantation. Cancers, 2022, 14, 2890.	3.7	2
75	Biliary Tract Cancer: A Survey Regarding the Current Oncological Daily Care Practice in Germany. Onkologie, 2012, 35, 755-760.	0.8	1
76	Sequence therapy in metastatic pancreatic cancer. Zeitschrift Fur Gastroenterologie, 2018, 56, 578-582.	0.5	1
77	Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinomaâ€"Who Will Benefit from a Secondary Resection?. Medicina (Lithuania), 2021, 57, 77.	2.0	1
78	Influence of cytotoxic tumor-infiltrating T lymphocytes on outcome in resectable pancreatic cancer: Results from the CONKO 001 trial.. Journal of Clinical Oncology, 2017, 35, 281-281.	1.6	1
79	A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, 330-330.	1.6	1
80	CONKO-008: Oxaliplatin (O)/folinic acid (FA)/5-fluorouracil (5-FU) (24h) in combination with lapatinib as second-line therapy in pancreatic cancer after gemcitabine failure: A phase I trial.. Journal of Clinical Oncology, 2012, 30, e14533-e14533.	1.6	1
81	Is gemcitabine (G) reuse possible in early recurrences after its adjuvant application in pancreatic adenocarcinoma (PA) treatment?. Journal of Clinical Oncology, 2015, 33, e15219-e15219.	1.6	0
82	Outcomes of gemcitabine (Gem)-based palliative first-line therapy in the treatment of recurrent disease or of initially unresectable pancreatic cancer (PC).. Journal of Clinical Oncology, 2015, 33, e15218-e15218.	1.6	0
83	Nabpaclitaxel plus gemcitabine in subjects with advanced pancreatic cancer who have cholestatic hyperbilirubenemia secondary to bile duct obstruction.. Journal of Clinical Oncology, 2016, 34, e15717-e15717.	1.6	0
84	Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI;) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 adenocarcinoma (mPAC) patients (pts) previously treated with gemcitabine-based therapy.. Journal of Clinical Oncology, 2016, 34, e15732-e15732.	1.6	0
85	A phase 1b (open-label)/phase 2 (randomized, double-blinded) study evaluating nab-paclitaxel and gemcitabine with or without olaratumab in first-line treatment of metastatic pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, TPS524-TPS524.	1.6	0
86	Phase Ib study of talimogene laherparepvec (T-VEC) injection into liver metastases (LMs) in combination with intravenous (IV) atezolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or colorectal cancer (CRC).. Journal of Clinical Oncology, 2019, 37, TPS725-TPS725.	1.6	0